Major funding for Parkinson’s research from the Norwegian Health Authorities
The Parkinson's research program led by Prof. Charalampos Tzoulis at the Neuro-SysMed Center has been strengthened by grants from the regional and national Norwegian Health Authorities, amounting to more than 3 million Euros.
Main content
The grants will fund two clinical studies led by Prof. Tzoulis' group: The NOPARK and N-DOSE studies.
NOPARK is a phase II, double-blinded randomized clinical trial of NAD-replenishment therapy by oral nicotinamide riboside (NR) in Parkinson's disease. The trial will determine whether NR has neuroprotective action and delays the motor and non-motor progression of Parkinson's disease. A total of 400 persons with Parkinson's disease who have had the diagnosis for up to 2 years will be recruited from all of Norway.
N-DOSE is a phase II, double-blinded randomized dose optimization study, which aims to determine the optimal dose of nicotinamide riboside (NR) for Parkinson's disease. The study will initiate in early 2022 and recruit a total of 80 patients with Parkinson's disease.
